Might 09, 2022
1 min learn
Alzamend Neuro Inc. has introduced the launch of a section 2A trial for its AL001 therapy for delicate to average Alzheimer’s dementia.
AL001 is being developed as an oral lithium-based remedy and has the potential to ship lithium carbonate to the mind whereas mitigating or avoiding present toxicities related to lithium.
“Advancing AL001 right into a section 2A scientific trial as deliberate marks an necessary milestone for Alzamend,” Alzamend CEO Stephan Jackman mentioned in a launched assertion. “We’re one step nearer to proving that AL001 might doubtlessly present clinicians with a significant enchancment over present lithium-based therapies and should represent a method of treating over 40 million Individuals affected by Alzheimer’s and different neurodegenerative illnesses and psychiatric issues.”
The primary affected person with delicate to average AD has obtained a dose of AL001 in a 12-month a number of ascending dose (MAD) examine, which is able to consider the security and tolerability of AL001 underneath multiple-dose, steady-state circumstances and decide the utmost tolerated dose in sufferers recognized with AD.
Based on the discharge, lithium has been well-characterized for security and is at the moment authorized in a number of formulations for the therapy of bipolar affective issues. Dosing for the MAD examine is predicated on a fraction of the everyday lithium dose utilized in these therapies.
“We look ahead to finishing the MAD examine and additional advancing scientific improvement of this promising potential therapeutic,” Jackman mentioned.